Neo-adjuvant Short Course Chemo-radiation Therapy in Locally Advanced Rectal Cancer Patients
Neo-adjuvant Short Course Chemo-radiotherapy in Locally Advanced Cancer Rectum
About this trial
This is an interventional treatment trial for Neo-adjuvant Short Course Chemo-radiotherapy in Locally Advanced Cancer Rectum focused on measuring CCRTH
Eligibility Criteria
Inclusion Criteria:
- Pathological confirmed cancer rectum
- Age between 20-80
- Clinical T3\4 or node positive disease by MRI
Exclusion Criteria:
- Early stage cancer rectum
- M1 disease confirmed by imaging or pathological
Sites / Locations
- Assiut UniversityRecruiting
Arms of the Study
Arm 1
Other
neoadjuvant chemo-radiation
Short-course RT: 5 fractions of 5 Gy to a total dose of 25 Gy over 5 consecutive days. IMRT plans are generated with 6 MV photons. Dose-escalated concurrent 5-FU: The 3 doses levels of 5-FU are 100, 150, and 200 mg/m2/d. 5-FU will be given by continuous infusion for 20 hours every day starting on the morning of radiation. mFOLFOX: will be given 2 weeks after concurrent chemoradiation for a total of 4 cycles, with each cycle being 14 days. Surgery will be omitted in patients with complete pathological response and proceed to adjuvant chemotherapy. If patient develops progressive or metastatic disease, he/she will be omitted from the investigators study. The surgery will be considered 4-8 weeks after end of therapy. Adjuvant mFOLFOX6: 6 cycles chemotherapy will begin between 4 weeks and 8 weeks after surgery. Toxicities assessment: be using National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0.